Calendar

January 2015
SunMonTueWedThuFriSat
 << <Jul 2017> >>
    123
45678910
11121314151617
18192021222324
25262728293031

Announce

Who's Online?

Member: 0
Visitors: 2

rss Syndication

Posts sent in: January 2015

Jan302015

Health Care Sector Update For 01/29/2015: Abt, Cah, Alxn - Nasdaq.com








Health Care Sector Update for 01/29/2015: NSPH,GENE,AAPY - NASDAQ.com






In health-care stocks news, Abbott Laboratories ( ABT ), a healthcare product developer, reported Q4 results that exceeded Street projections on EPS but missed on total revenues. The company reported Q4 adjusted EPS of $0.71, up from $0.58 in the same period a year ago and topping analyst estimates of $0.68. Over the past 52 weeks, the company has traded between $35.65 and $46.50. Meanwhile Cardinal Health ( CAH ) reported Q2 earnings and revenue that beat the Street view on Thursday. Cardinal reported earnings of $1.20 per share versus the analyst consensus of $1.10 per share, according to Thomson Reuters. Over the past 52 weeks, the company has traded between $63.06 and $87.33. And Alexion Pharmaceuticals ( ALXN ) reported Q4 results that beat the Street view on both EPS and total revenues. The company reported Q4 adjusted EPS of $1.30, up from $0.87 in the same period a year ago and beating analyst estimates of $1.27. Over the past 52 weeks, the company has traded between $128.89 go and $203.30.
Health Care Sector Update for 01/29/2015: ABT, CAH, ALXN - NASDAQ.com










But perhaps limiting Thursday's retreat for NSPH shares was the company's late Wednesday reporting preliminary Q4 revenue topping analyst estimates. It said revenue grew 35.3% over year-ago levels to around $4.6 million, topping the Capital IQ consensus by around $280,000. New customer placements during the quarter were up more than 34% over the final three months of 2013. NSPH shares were down 19% at 25 cents each, matching its session low and only 3 cents higher than its Jan. 26 all-time low. Heading into Thursday's trade, the stock already had receded more than 85% over the past 12 months. In other sector news, (+) GENE, (+235.7%) Said as many as six new diagnosis and treatment centers will soon begin offering its BREVAGenplus test for breast cancer to at-risk patients, resulting in accelerating sales growth during the second half of 2015 and beyond. (-) APPY, (-72.3%) FDA determines the APPY1 test for appendicitis was not substantially equivalent to standard of care based upon data and information submitted by the company in its 510(k) submission.
Health Care Sector Update for 01/29/2015: NSPH,GENE,AAPY - NASDAQ.com




Admin · 111 views · Leave a comment